Imatinib (STI571)

DRUG3 trials

Sponsors

University of Bologna, Novartis Pharmaceuticals, Poitiers University Hospital

Conditions

Chronic Myeloid LeukemiaChronic Myeloid Leukemia (CML)Gastrointestinal Stromal Tumor (GIST)

Phase 2

Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase

CompletedNCT00514969

University of BolognaChronic Myeloid Leukemia

Start: 2000-08-31Updated: 2007-08-10

Phase 3

A Study of Nilotinib Versus Imatinib in GIST Patients

CompletedNCT00785785

Novartis PharmaceuticalsGastrointestinal Stromal Tumor (GIST)

Start: 2009-03-31End: 2014-10-31Updated: 2016-06-16

Unknown Phase

Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial

Enrolling by invitationNCT06646978

Poitiers University HospitalChronic Myeloid Leukemia (CML)

Start: 2024-05-01End: 2025-05-31Target: 787Updated: 2024-10-17

Related Papers

Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.

2015-04-1484 citations

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.

2008-10-0670 citations